Nimodipine for primary degenerative, mixed and vascular dementia.
about
Huperzine A for vascular dementiaValsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer diseaseThe dendritic hypothesis for Alzheimer's disease pathophysiology.Neuroprotective and neuroregenerative effects of nimodipine in a model system of neuronal differentiation and neurite outgrowth.Dementia and osteoporosis in a geriatric population: Is there a common link?L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's diseaseNILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease.Unintended effects of cardiovascular drugs on the pathogenesis of Alzheimer's diseaseRationale and design of a double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of nimodipine in preventing cognitive impairment in ischemic cerebrovascular events (NICE)Blood pressure and dementia - a comprehensive review.Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews.Cerebral oxygenation and haemodynamic effects induced by nimodipine in healthy subjects.Differential rescue of spatial memory deficits in aged rats by L-type voltage-dependent calcium channel and ryanodine receptor antagonism.Caloric intake, dietary lifestyles, macronutrient composition, and alzheimer' disease dementiaVascular cognitive impairment: disease mechanisms and therapeutic implications.A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drug.Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine.Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review.Efficacy and safety assessment of acupuncture and nimodipine to treat mild cognitive impairment after cerebral infarction: a randomized controlled trialNimodipine inhibits IL-1β release stimulated by amyloid β from microglia.A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocolA 10-year follow-up study of the association between calcium channel blocker use and the risk of dementia in elderly hypertensive patientsDrug repositioning: an opportunity to develop novel treatments for Alzheimer's disease.Pharmacotherapeutic targets in Alzheimer's diseaseCalcium in the initiation, progression and as an effector of Alzheimer's disease pathology.The dysregulation of intracellular calcium in Alzheimer disease.Neuronal calcium signaling, mitochondrial dysfunction, and Alzheimer's disease.P/Q-type calcium channel modulators.Calcium channel blockers and dementia.An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations.Treatment of vascular dementia. Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology.Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease
P2860
Q24241186-5977AD9E-35AA-46AD-B11C-EBD639BE4F52Q24675823-D710B611-DF21-44D1-8F28-31327492B508Q27687404-E1D4C698-6A7B-4ECF-A637-6CD473CF3B21Q30316856-89144817-826C-4D4B-B521-F5EAC144BCF5Q33696083-2E28F504-3FA2-4F36-8BD5-2B258CBD82E1Q34135977-7408E425-AEFE-4E6F-B325-AF88214ACDB9Q34327761-5EF31DDB-C522-4FB9-8517-5314C940B5ADQ34350595-E3A424BF-19F6-4E4B-8071-90383ACAE541Q34403971-89D87E2C-8033-4174-A061-93D8C6ED2327Q34409397-168DA8CC-5724-44A9-BAD0-5297BBADF410Q34523922-628F27A4-C0CD-4DF1-BBCE-01448EF69535Q34583326-6CF32D71-B7E1-4586-82D1-8356A80D5166Q34603211-FEAF5B67-DD1D-4DC4-A5AC-90A81470A606Q35130936-73D77EBE-8BAD-4D9C-8D74-6D42A12DD88FQ35197111-38F2CABC-6432-411D-AAAA-98A7252A507FQ35232631-463528FA-CC44-4B5B-8529-5250A80B35DAQ35743824-92C66CB5-6B53-445D-BCEF-917F7046B19BQ35780850-3CB65CE5-8A0E-4F99-9573-75E157F8C0A6Q36131600-F9ED9C6B-3563-4595-90A9-487953A59109Q36476748-8753793E-7181-481A-B5A9-303899069DC4Q37106589-E9354C18-91B8-4B67-AEFD-E3C96DC4FE82Q37176098-AFCB7CD1-FDF5-4D7F-9083-376D08AFFDF8Q37279999-708C45A3-66FE-4162-9755-4C5158A5AF26Q37295067-C7E75A63-FC48-4338-813C-AD56E8D54ED0Q37570600-58907DA8-1C8A-4542-9460-5F82AA332DC2Q37676636-668373E0-1084-45AB-A22B-0ADB654B77D2Q37736181-C5D02FFC-7AAD-4EF2-B85F-7A7E227F710DQ38016449-FD7A83AD-30D7-42E0-920A-300335FC3A9CQ38103603-839F2822-556E-42D8-8259-CA8271142A7BQ43557976-BE797258-51DA-46A8-AE7C-6E4D95FBAE95Q47128027-E2820BB1-7F31-4AD8-95E6-B60D8C4A6144Q58566954-7E520060-8B74-4BC8-8DF4-F4CAFA3E76BD
P2860
Nimodipine for primary degenerative, mixed and vascular dementia.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Nimodipine for primary degenerative, mixed and vascular dementia
@nl
Nimodipine for primary degenerative, mixed and vascular dementia.
@ast
Nimodipine for primary degenerative, mixed and vascular dementia.
@en
type
label
Nimodipine for primary degenerative, mixed and vascular dementia
@nl
Nimodipine for primary degenerative, mixed and vascular dementia.
@ast
Nimodipine for primary degenerative, mixed and vascular dementia.
@en
altLabel
Nimodipine for primary degenerative, mixed and vascular dementia
@en
prefLabel
Nimodipine for primary degenerative, mixed and vascular dementia
@nl
Nimodipine for primary degenerative, mixed and vascular dementia.
@ast
Nimodipine for primary degenerative, mixed and vascular dementia.
@en
P2093
P2860
P433
P577
P698
P1476
Nimodipine for primary degenerative, mixed and vascular dementia
@en
Nimodipine for primary degenerative, mixed and vascular dementia.
@en
P2093
J M López-Arrieta
López-Arrieta
P2860
P304
P356
10.1002/14651858.CD000147
P407
P433
P577
2000-01-01T00:00:00Z
2001-01-01T00:00:00Z
2002-01-01T00:00:00Z